IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0006425.html
   My bibliography  Save this article

The Impact of National Institutes of Health Funding on U.S. Cardiovascular Disease Research

Author

Listed:
  • Radmila Lyubarova
  • Brandon K Itagaki
  • Michael W Itagaki

Abstract

Background: Intense interest surrounds the recent expansion of US National Institutes of Health (NIH) budgets as part of economic stimulus legislation. However, the relationship between NIH funding and cardiovascular disease research is poorly understood, making the likely impact of this policy change unclear. Methods: The National Library of Medicine's PubMed database was searched for articles published from 1996 to 2006, originating from U.S. institutions, and containing the phrases “cardiolog,” “cardiovascular,” or “cardiac,” in the first author's department. Research methodology, journal of publication, journal impact factor, and receipt of NIH funding were recorded. Differences in means and trends were tested with t-tests and linear regression, respectively, with P≤0.05 for significance. Results: Of 117,643 world cardiovascular articles, 36,684 (31.2%) originated from the U.S., of which 10,293 (28.1%) received NIH funding. The NIH funded 40.1% of U.S. basic science articles, 20.3% of overall clinical trials, 18.1% of randomized-controlled, and 12.2% of multicenter clinical trials. NIH-funded and total articles grew significantly (65 articles/year, P

Suggested Citation

  • Radmila Lyubarova & Brandon K Itagaki & Michael W Itagaki, 2009. "The Impact of National Institutes of Health Funding on U.S. Cardiovascular Disease Research," PLOS ONE, Public Library of Science, vol. 4(7), pages 1-8, July.
    • Handle: RePEc:plo:pone00:0006425
    DOI: 10.1371/journal.pone.0006425
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006425
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0006425&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0006425?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Joseph Dimasi & Henry Grabowski & John Vernon, 1995. "R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 2(2), pages 201-219.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wei Cheng, 2022. "Productivity spillovers in endogenous coauthor networks," Empirical Economics, Springer, vol. 63(6), pages 3159-3183, December.
    2. Chris W. Belter, 2013. "A bibliometric analysis of NOAA’s Office of Ocean Exploration and Research," Scientometrics, Springer;Akadémiai Kiadó, vol. 95(2), pages 629-644, May.
    3. Belén Álvarez-Bornstein & Fernanda Morillo & María Bordons, 2017. "Funding acknowledgments in the Web of Science: completeness and accuracy of collected data," Scientometrics, Springer;Akadémiai Kiadó, vol. 112(3), pages 1793-1812, September.
    4. David Hsiehchen & Magdalena Espinoza & Antony Hsieh, 2017. "Disease burden and the advancement of biomedical knowledge," Scientometrics, Springer;Akadémiai Kiadó, vol. 110(1), pages 321-333, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    2. Giuseppe Moscarini & Lones Smith, 1998. "Wald Revisited: The Optimal Level of Experimentation," Working papers 98-4, Massachusetts Institute of Technology (MIT), Department of Economics.
    3. Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
    4. Richard T. Thakor & Andrew W. Lo, 2015. "Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry," NBER Working Papers 20903, National Bureau of Economic Research, Inc.
    5. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
    6. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    7. Fossett, Sarah J. & Wunnava, Phanindra V., 2017. "Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs," IZA Discussion Papers 10817, Institute of Labor Economics (IZA).
    8. Chok, Jay Inghwee, 2009. "Regulatory dependence and Scientific Advisory Boards," Research Policy, Elsevier, vol. 38(5), pages 710-725, June.
    9. Finn Valentin & Henrich Dahlgren & Rasmus Lund Jensen, 2006. "Research Strategies in Science-based Start-ups - Effects on performance in Danish and Swedish biotechnology," DRUID Working Papers 06-11, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
    10. Hans H. Bauer & Marc Fischer & Volker Pfahlert, 2001. "Lohnt sich für Pharmaunternehmen der Markteintritt als Late Mover? — Ergebnisse einer Rentabilitätsanalyse," Schmalenbach Journal of Business Research, Springer, vol. 53(6), pages 632-648, September.
    11. Philip Joos & Alexei Zhdanov, 2008. "Earnings and Equity Valuation in the Biotech Industry: Theory and Evidence," Financial Management, Financial Management Association International, vol. 37(3), pages 431-460, September.
    12. José Lejarraga & Ester Martinez-Ros, 2014. "Size, R&D productivity and Decision Styles," Small Business Economics, Springer, vol. 42(3), pages 643-662, March.
    13. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
    14. David J. Ravenscraft & William F. Long, 2000. "Paths to Creating Value in Pharmaceutical Mergers," NBER Chapters, in: Mergers and Productivity, pages 287-326, National Bureau of Economic Research, Inc.
    15. Martin Backfisch, 2017. "Have Pharmaceutical R&D Project Success Rates Decreased? A Critical Review and New Empirical Results," MAGKS Papers on Economics 201746, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
    16. Bauer, Hans H. & Fischer, Marc, 2000. "Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products," International Business Review, Elsevier, vol. 9(6), pages 703-725, December.
    17. Burak Dindaroglu, 2011. "R&D Productivity and Firm Size in Semiconductors and Pharmaceuticals: Evidence from Citation Yields," Working Papers 1101, Izmir University of Economics.
    18. Mc Namara, Peter & Baden-Fuller, Charles, 2007. "Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms," Research Policy, Elsevier, vol. 36(4), pages 548-565, May.
    19. José Lejarraga & Ester Martínez-Ros, 2010. "Revisiting the Size-R&D Productivity Relation: Introducing the Mediating Role of Decision-Making Style on the Scale and Quality of Innovative Output," Working Papers 1006, Departament Empresa, Universitat Autònoma de Barcelona, revised Mar 2010.
    20. Eduardo S. Schwartz, 2003. "Patents and R&D as Real Options," NBER Working Papers 10114, National Bureau of Economic Research, Inc.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0006425. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.